HDAC2 and breast carcinoma: Mocetinostat, an inhibitor of HDAC1-3 and HDAC11, induced the expression of tumor suppressor Fyn-related kinase in basal-like breast cancer and showed antitumor effects in those overexpressing HDAC2 [154, 155].